CSIMarket
 


Aurinia Pharmaceuticals Inc   (AUPH)
Other Ticker:  
 

Aurinia Pharmaceuticals Inc 's Working Capital Ratio

AUPH's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth


In the wake of the increase in Current Liabilities in the forth quarter 2023, Working Capital Ratio fell to 5.5 a new company low.

Within Major Pharmaceutical Preparations industry 13 other companies have achieved higher Working Capital Ratio than Aurinia Pharmaceuticals Inc in forth quarter 2023. While Working Capital Ratio total ranking has improved so far during the IV Quarter 2023 to 123, from total ranking in the third quarter 2023 at 693.

Explain Working Capital Ratio
How much in Current Assets AUPH´s has?
What is the value of AUPH´s Current Liabilities?


AUPH Working Capital Ratio (Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Current Liabilities Change 67.41 % 80.89 % 83.12 % 28.08 % 16.47 %
Y / Y Current Assets Change -4.01 % -7.23 % -8.23 % -11.3 % -13.79 %
Working Capital Ratio MRQ 5.5 5.77 6.75 10.08 9.6
AUPH's Total Ranking # 123 # 693 # 221 # 471 # 224
Seq. Current Liabilities Change 4.46 % 19.83 % 46.65 % -8.81 % 12.88 %
Seq. Current Assets Change -0.39 % 2.54 % -1.83 % -4.27 % -3.73 %



Working Capital Ratio forth quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 14
Healthcare Sector # 27
Overall Market # 123


Working Capital Ratio Statistics
High Average Low
27.9 15 5.5
(Dec 31 2019)   (Dec 31 2023)




Financial Statements
Aurinia Pharmaceuticals Inc 's Current Liabilities $ 77 Millions Visit AUPH's Balance sheet
Aurinia Pharmaceuticals Inc 's Current Assets $ 425 Millions Visit AUPH's Balance sheet
Source of AUPH's Sales Visit AUPH's Sales by Geography


Cumulative Aurinia Pharmaceuticals Inc 's Working Capital Ratio

AUPH's Working Capital Ratio for the trailling 12 Months

AUPH Working Capital Ratio

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Current Liabilities TTM Growth 67.41 % 80.89 % 83.12 % 28.08 % 16.47 %
Y / Y Current Assets TTM Growth -4.01 % -7.23 % -8.23 % -11.3 % -13.79 %
Working Capital Ratio TTM 6.64 7.64 9.14 10.94 11.95
Total Ranking TTM # 1620 # 3624 # 481 # 3388 # 2601
Seq. Current Liabilities TTM Growth 4.46 % 19.83 % 46.65 % -8.81 % 12.88 %
Seq. Current Assets TTM Growth -0.39 % 2.54 % -1.83 % -4.27 % -3.73 %


On the trailing twelve months basis Due to rise in Current Liabilities in the IV Quarter 2023 to $77.19 millions, cumulative Working Capital Ratio decreased to 6.64 below the Aurinia Pharmaceuticals Inc average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 107 other companies have achieved higher Working Capital Ratio than Aurinia Pharmaceuticals Inc . While Working Capital Ratio overall ranking has improved so far to 1620, from total ranking during the twelve months ending third quarter 2023 at 3624.

Explain Working Capital Ratio
How much in Current Assets AUPH´s has?
What is the value of AUPH´s Current Liabilities?

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 108
Healthcare Sector # 277
Within the Market # 1620


trailing twelve months Working Capital Ratio Statistics
High Average Low
27.9 13.58 6.64
(Dec 31 2019)   (Dec 31 2023)




Companies with similar Working Capital Ratio in the quarter ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Working Capital RatioDec 31 2023 MRQ Current AssetsDec 31 2023 MRQ Current Liabilities
Keros Therapeutics Inc   14.25 $ 347.293  Millions$ 24.373  Millions
Compass Pathways Plc  13.33 $ 261.296  Millions$ 19.604  Millions
Vyne Therapeutics Inc   12.73 $ 95.963  Millions$ 7.538  Millions
Rallybio Corporation  12.39 $ 114.789  Millions$ 9.263  Millions
Rezolute Inc   12.00 $ 96.085  Millions$ 8.008  Millions
Immuneering Corporation  11.81 $ 89.084  Millions$ 7.545  Millions
Cryoport inc   11.77 $ 536.792  Millions$ 45.610  Millions
Cassava Sciences Inc  11.62 $ 129.633  Millions$ 11.158  Millions
Virios Therapeutics Inc   11.62 $ 4.165  Millions$ 0.359  Millions
Anaptysbio Inc   11.41 $ 406.835  Millions$ 35.665  Millions
Vanda Pharmaceuticals Inc   11.26 $ 432.946  Millions$ 38.460  Millions
Prothena Corporation Public Limited Company  11.24 $ 639.282  Millions$ 56.891  Millions
Cymabay Therapeutics Inc   10.96 $ 403.802  Millions$ 36.843  Millions
Ovid Therapeutics Inc   10.72 $ 109.598  Millions$ 10.228  Millions
Spyre Therapeutics Inc   10.68 $ 341.528  Millions$ 31.978  Millions
Chimerix Inc   10.25 $ 189.110  Millions$ 18.443  Millions
Aprea Therapeutics Inc   10.24 $ 22.521  Millions$ 2.199  Millions
Milestone Pharmaceuticals inc   10.11 $ 73.032  Millions$ 7.226  Millions
Summit Therapeutics Inc   9.30 $ 189.712  Millions$ 20.405  Millions
Ac Immune Sa  9.22 $ 125.153  Millions$ 13.576  Millions
Sol gel Technologies Ltd   9.10 $ 41.167  Millions$ 4.522  Millions
Oncolytics Biotech Inc   9.01 $ 29.241  Millions$ 3.246  Millions
Inmed Pharmaceuticals Inc   8.97 $ 11.810  Millions$ 1.316  Millions
Lipella Pharmaceuticals Inc   8.90 $ 3.429  Millions$ 0.385  Millions
Lipocine Inc   8.74 $ 22.861  Millions$ 2.614  Millions
Neurogene Inc   8.72 $ 200.348  Millions$ 22.973  Millions
Abcellera Biologics Inc   8.72 $ 871.985  Millions$ 100.055  Millions
Xoma Corporation  8.68 $ 169.313  Millions$ 19.499  Millions
Artelo Biosciences Inc   8.51 $ 10.980  Millions$ 1.291  Millions
Capricor Therapeutics inc   8.14 $ 50.855  Millions$ 6.250  Millions

Date modified: 2024-02-15T15:53:17+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com